SOURCE: StockCall

StockCall

December 02, 2010 08:17 ET

Opinions on Biogen Idec Inc. and Genzyme Corp. - If They Can't Make It, They Buyout those That Can

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 2, 2010) -  www.stockcall.com/ offers investors comprehensive research on the biotechnology industry and has completed analytical research on Biogen Idec Inc. (NASDAQ: BIIB) and Genzyme Corp. (NASDAQ: GENZ). Register with us today at www.stockcall.com/ to have free access to these researches. 

Many big pharmaceutical and biotechnology companies are in hot waters with the onset of huge patent cliffs during the next three years. After cutting their budgets during their recent fiscal difficulties, many companies are beginning to search out other means besides R&D to secure their pipelines. This creates value for smaller companies in the sector with strong incoming product lines as they become takeover targets for larger companies looking to patch holes. At this moment in time, the Sanofi's offer for Genzyme Corp. is making the headlines. In the aggressive acquisition market, many large companies are willing to marginally overpay in order to ensure they have something to work with coming down the pipeline. Investors looking for free research on Genzyme Corp. are welcome to sign up at www.stockcall.com/GENZ021210.pdf

www.stockcall.com/ is an online platform where investors doing their due-diligence on the biotechnology industry can have easy and free access to our analyst research and opinions on Biogen Idec Inc. and Genzyme Corp.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Good news for the sector involves the FDA's decision to provide patent protection for biosimilar generics. Previously, the Food and Drug Administration did not regulate the approval of biosimilar generic drugs, only drugs with chemical compounds. The FDA recently decided to give the biosimilars twelve years of patent protection signaling a victory for the sector. This had been an area of persistent governmental lobbying. Healthcare reform fee requirements, pay-for-delay patent reform, and coverage gaps remain issues the sector is working on in Washington. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the biotechnology industry.

Taking a look at results for the third quarter 2010, Biogen Idec Inc. posted net income of $254.1 million an 8.5% decline on the back of elevated costs and expenses which include acquisition charges. Revenue on the other hand was up 5% to $1.18 billion. Investors looking for free research on Biogen Idec Inc. are welcome to sign up at www.stockcall.com/BIIB021210.pdf.

Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information